Once a promising cancer treatment, the failure of PARP inhibitors in the clinic may be due to flawed preclinical studies.
The Nutshell
Daily News Roundup
Most Recent
The NIH plans an extra layer of review for scientists with at least $1.5 million in existing grants.
Graduate students ask for more federal research support.
A new report outlines ways in which omics-based technologies can be shuttled more safely and effectively from the bench to the clinic.
Mice “avatars” grafted with patient tumor tissue help identify effective drug regimens.
Through a confluence of events, academic medical centers could lose 10 percent of their revenue in the coming years.
GlaxoSmithKline and Johnson & Johnson contribute a total of $100 million to early-stage biotech endeavors.
One biopsy may not provide enough information about the array of mutations in cancer to devise treatments based on a tumor’s genetic profile.
Early experiments show that a hybrid form of the common pain reliever can effectively inhibit the growth of many tumor types.
A National Academies of Science panel is nearly done evaluating research institutions with a critical eye on the quality of undergraduate education.
Subjects
- cancer
- cell & molecular biology
- culture
- disease/medicine
- ecology
- evolution
- funding
- genetics & genomics
- NIH
- policy
Sub Categories
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
